These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27097724)

  • 1. Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families.
    Kasule GW; Kateete DP; Joloba ML
    BMC Infect Dis; 2016 Apr; 16():173. PubMed ID: 27097724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on the genotypes of 260 Mycobacterium tuberculosis isolates by Spoligotyping method in Jiangsu province, China].
    Liu Q; Xu WG; Wan KL; Wang JM; Yang DD; Lü B; Shao Y; Wang H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Dec; 32(12):1250-4. PubMed ID: 22336611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kampala, Uganda.
    Asiimwe BB; Ghebremichael S; Kallenius G; Koivula T; Joloba ML
    BMC Infect Dis; 2008 Jul; 8():101. PubMed ID: 18662405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains isolated from patients in Kazakhstan.
    Hillemann D; Kubica T; Agzamova R; Venera B; Rüsch-Gerdes S; Niemann S
    Int J Tuberc Lung Dis; 2005 Oct; 9(10):1161-7. PubMed ID: 16229229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insight into the molecular characterization of isoniazid and rifampicin resistant Mycobacterium tuberculosis strains from Saudi Arabia.
    Varghese B; Hillemann A; Wijayanti DR; Shoukri M; Al-rabiah F; Al-Omari R; Al-Hajoj S
    Infect Genet Evol; 2012 Apr; 12(3):549-56. PubMed ID: 22326932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
    Valvatne H; Syre H; Kross M; Stavrum R; Ti T; Phyu S; Grewal HM
    J Antimicrob Chemother; 2009 Oct; 64(4):694-701. PubMed ID: 19710078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
    Schön T; Juréen P; Giske CG; Chryssanthou E; Sturegård E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA
    J Antimicrob Chemother; 2009 Oct; 64(4):786-93. PubMed ID: 19633001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis drugs in Indonesia.
    Lisdawati V; Puspandari N; Rif'ati L; Soekarno T; M M; K S; Ratnasari L; Izzatun N; Parwati I
    BMC Infect Dis; 2015 Aug; 15():366. PubMed ID: 26297576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
    Coban AY; Bilgin K; Uzun M; Durupinar B
    Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Diversity of Mycobacterium tuberculosis Isolates from Assam, India: Dominance of Beijing Family and Discovery of Two New Clades Related to CAS1_Delhi and EAI Family Based on Spoligotyping and MIRU-VNTR Typing.
    Devi KR; Bhutia R; Bhowmick S; Mukherjee K; Mahanta J; Narain K
    PLoS One; 2015; 10(12):e0145860. PubMed ID: 26701129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
    Colangeli R; Jedrey H; Kim S; Connell R; Ma S; Chippada Venkata UD; Chakravorty S; Gupta A; Sizemore EE; Diem L; Sherman DR; Okwera A; Dietze R; Boom WH; Johnson JL; Mac Kenzie WR; Alland D;
    N Engl J Med; 2018 Aug; 379(9):823-833. PubMed ID: 30157391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains.
    Khameneh B; Fazly Bazzaz BS; Amani A; Rostami J; Vahdati-Mashhadian N
    Microb Pathog; 2016 Apr; 93():83-7. PubMed ID: 26602814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using
    Genestet C; Ader F; Pichat C; Lina G; Dumitrescu O; Goutelle S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India.
    Singhal P; Dixit P; Singh P; Jaiswal I; Singh M; Jain A
    Indian J Med Res; 2016 Mar; 143(3):341-7. PubMed ID: 27241648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characteristics of rifampin and isoniazid resistant Mycobacterium tuberculosis strains from Beijing, China.
    Jiao WW; Mokrousov I; Sun GZ; Li M; Liu JW; Narvskaya O; Shen AD
    Chin Med J (Engl); 2007 May; 120(9):814-9. PubMed ID: 17531124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda.
    Ssengooba W; Meehan CJ; Lukoye D; Kasule GW; Musisi K; Joloba ML; Cobelens FG; de Jong BC
    Infect Genet Evol; 2016 Jun; 40():8-16. PubMed ID: 26917365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda.
    Joloba ML; Whalen CC; Cave DM; Eisenach KD; Johnson JL; Okwera A; Morrissey A; Bajaksouzian S; Feagin J; Mugerwa R; Ellner J; Jacobs MR
    East Afr Med J; 2000 Feb; 77(2):111-5. PubMed ID: 10774085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of the Beijing family genotypes of Mycobacterium tuberculosis in Taiwan.
    Jou R; Chiang CY; Huang WL
    J Clin Microbiol; 2005 Jan; 43(1):95-100. PubMed ID: 15634956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
    Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
    Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
    Martin A; Panaiotov S; Portaels F; Hoffner S; Palomino JC; Angeby K
    J Antimicrob Chemother; 2008 Jul; 62(1):56-64. PubMed ID: 18407918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.